Increasing utilization of neoadjuvant chemotherapy for muscle-invasive bladder cancer in the United States

Current Urology Reports

Volumn 15, Issue 4, 2014, Pages

  Keegan, Kirk A ^a   Zaid, Harras B ^b   Patel, Sanjay G ^c   Chang, Sam S ^b,d  

^a SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bladder cancer; Chemotherapy; Neoadjuvant therapy; Review; Utilization

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER ADJUVANT THERAPY; CANCER SURGERY; COMORBIDITY; CYSTECTOMY; HEALTH CARE UTILIZATION; HUMAN; MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; PREOPERATIVE TREATMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; UNITED STATES; ADJUVANT THERAPY; BLADDER TUMOR; PATHOLOGY; SMOOTH MUSCLE; TRANSITIONAL CELL CARCINOMA; TUMOR INVASION; UTILIZATION REVIEW;

CARCINOMA, TRANSITIONAL CELL; CYSTECTOMY; HUMANS; MUSCLE, SMOOTH; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; UNITED STATES; URINARY BLADDER NEOPLASMS;

EID: 84894288501     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-014-0394-5     Document Type: Review

References (37)

1. .•• Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859-66. Seminal SWOG 8710 clinical trial demonstrating overall survival and significant downstaging attributed to NAC regimen compared to RC alone.
2. Advanced Bladder Cancer Overview Collaboration. Neoadjuvant chemotherapy for invasive bladder cancer. Cochrane Database Syst Rev. 2005;2:CD005246.
3. Advanced Bladder Cancer Collaboration. Neoadjuvant chemotherapy for invasive bladder cancer. Cochrane Database Syst Rev. 2009;1:1-32.
4. Dash A, Pettus JA, Herr HW, Bochner BH, Dalbagni G, Donat SM, et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer. 2008;113:2471-7.
5. Smith DC, Mackler NJ, Dunn RL, Hussain M, Wood D, Lee CT, et al. Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder. J Urol. 2008;180:2384-8. discussion 2388.
6. Fairey AS, Daneshmand S, Quinn D, Dorff T, Dorin R, Lieskovsky G, et al. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/ vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California. Urol Oncol. 2013;8:1737-43.
7. Meeks JJ, Bellmunt J, Bochner BH, Clarke NW, Daneshmand S, Galsky MD, et al. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2012;62:523-33.
8. International collaboration of trialists. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy formuscle-invasive bladder cancer: a randomised controlled trial. Lancet. 1999;354:533-40.
9. Schultz PK, Herr HW, Zhang ZF, Bajorin DF, Seidman A, Sarkis A, et al. Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. J Clin Oncol. 1994;12:1394-401. (Pubitemid 24206237)
10. deVere White RW, Katz MH, Steinberg GD. The case for neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer. J Urol. 2009;181:1994-7.
11. Lehmann J, Retz M, Stöckle M. Chemotherapy in the post-MVAC era: the case for adjuvant chemotherapy. World J Urol. 2002;20:144-50.
12. Lehmann J, Retz M, Wiemers C, Beck J, Thüroff J, Weining C, et al. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol. 2005;23:4963-74. (Pubitemid 46224002)
13. Raghavan D, Quinn D, Skinner DG, Stein JP. Surgery and adjunctive chemotherapy for invasive bladder cancer. Surg Oncol. 2002;11:55-63. (Pubitemid 34603364)
14. Raghavan D, Burgess E, Gaston KE, Haake MR, Riggs SB. Neoadjuvant and adjuvant chemotherapy approaches for invasive bladder cancer. Semin Oncol. 2012;39:588-97.
15. Porter MP, Kerrigan MC, Donato BMK, Ramsey SD. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. Urol Oncol: Semin Orig Investig. 2011;29:252-8.
16. Lund JL, Stürmer T, Harlan LC, Sanoff HK, Sandler RS, Brookhart MA, et al. Identifying Specific Chemotherapeutic Agents in Medicare Data: A Validation Study. Med Care. 2013;51(5):e27-34.
17. Warren JL, Harlan LC, Fahey A, Virnig BA, Freeman JL, Klabunde CN, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002;40:IV-55-61.
18. David KA, Milowsky MI, Ritchey J, Carroll PR, Nanus DM. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report fromthe national cancer data base. J Urol. 2007;178:451-4. (Pubitemid 47030482)
19. Fedeli U, Fedewa SA, Ward EM. Treatment of muscle invasive bladder cancer: evidence from the national cancer database, 2003 to 2007. J Urol. 2011;185:72-8.
20. .• Raj GV, Karavadia S, Schlomer B, Arriaga Y, Lotan Y, Sagalowsky A, et al. Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. Cancer. 2010;117:276-82. Patterns of care for perioperative chemotherapy use in high-volume tertiary care facility. Patient age, comorbidity, and apparent clinically localized disease significant predictors for withholding NAC.
21. .• Sandhu GS, Luo S, Zeringue A, Carson KR, Nepple KR, Strope SA, et al. Utilization and predictors of neoadjuvant chemotherapy for muscle-invasive bladder cancer in the Veterans Health Administration. J Clin Oncol 2012;30(15) Suppl; Abstract 4594. Recent data demonstrating increased use of NAC in VA system consistent with evidence-based practice.
22. • Keegan KA, Morgan TM, Resnick MJ, Anderson CB, Ni S, Davis R, et al. Changing utilization of neoadjuvant and adjuvant chemotherapies for muscle-invasive urothelial carcinoma after publication of landmark manuscripts. J Urol. 2012;187:e216-7. Abst 527 Recent data to address the specific impact of level 1 data on utilization of perioperative chemotherapy. 42% higher odds of NAC utilization after 2003, the year of SWOG 8710 data.
23. .• Zaid HB, Patel SG, Stimson CJ, Resnick MJ, Cookson MS, Barocas DA, Chang SS. Trends in the Utilization of Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Results From the National Cancer Database. Urology. 2014;83(1):75-80. Large scale, administrative data demonstrating increased utilization of NAC from 10.2% to 20.9%, and significant tumor downstaging associated with NAC protocols.
24. Herr HW, Dotan Z, Donat SM, Bajorin DF. Defining optimal therapy for muscle invasive bladder cancer. J Urol. 2007;177:437-43. (Pubitemid 46075130)
25. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19:666-75. (Pubitemid 32120143)
26. Montgomery JS, Miller DC, Weizer AZ. Quality indicators in the management of bladder cancer. J Natl Compr Canc Netw. 2013;11:492-500.
27. Cooperberg MR, Porter MP, Konety BR. Candidate quality of care indicators for localized bladder cancer. Urol Oncol: Semin Orig Investig. 2009;27:435-42.
28. Feifer A, Taylor JM, Shouery M, et al. Multi-institutional quality-of-care initiative for nonmetastatic, muscle-invasive, transitional cell carcinoma of the bladder: Phase I. J Clin Oncol. 2011;29 Suppl 7; Abstract 240.
29. Cowan N, Chen Y, La Rochelle J, Amling C, Koppie T. Neoadjuvant chemotherapy use in bladder cancer: a survey of current practice and opinions. J Urol. 2013;189:e587-8. Abst 1435.
30. Tsao C-K, Moshier E, Seng SM, Godbold J, Grossman S, Winston J, et al. Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer. Clin Genitourin Cancer. 2012;10:15 - 20.
31. Raj GV, Iasonos A, Herr H, Donat SM. Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer. J Clin Oncol. 2006;24:3095-100. (Pubitemid 46638946)
32. Canter D, Viterbo R, Kutikov A, Wong Y-N, Plimack E, Zhu F, et al. Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy. Urology. 2011;77:160-5.
33. Dash A, Galsky MD, Vickers AJ, Serio AM, Koppie TM, Dalbagni G, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer. 2006;107:506-13. (Pubitemid 44107210)
34. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40:IV.
35. Newman LA, Lee CT, Parekh LP, Stewart AK, Thomas CR, Beltran RA, et al. Use of the National Cancer Data Base to develop clinical trials accrual targets that are appropriate for minority ethnicity patients: a report from the American College of Surgeons Oncology Group (ACOSOG) Special Population Committee. Cancer. 2006;106:188-95. (Pubitemid 43032564)
36. Menck HR, Bland KI, Eyre HJ, Cunningham MP, Fremgen A, Murphy GP, et al. Clinical highlights from the National Cancer Data Base, 1998. CA: Cancer J Clin. 1998;48:134-45. (Pubitemid 28383259)
37. Lotan Y, Bagrodia A, Passoni N, Rachakonda V, Kapur P, Arriaga Y, et al. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy. European Urology. 2013;64:465-71.